These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30801965)

  • 1. Chiral Pool Synthesis, Biological Evaluation and Molecular Docking Studies of C-Furanosidic LpxC Inhibitors.
    Dreger A; Kharwb O; Agoglitta O; Bülbül EF; Melesina J; Sippl W; Holl R
    ChemMedChem; 2019 Apr; 14(8):871-886. PubMed ID: 30801965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, biological evaluation, and molecular docking studies of deoxygenated C-glycosides as LpxC inhibitors.
    Dreger A; Hoff K; Agoglitta O; Bülbül EF; Melesina J; Sippl W; Holl R
    Bioorg Chem; 2021 Dec; 117():105403. PubMed ID: 34758434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chiral pool synthesis and biological evaluation of C-furanosidic and acyclic LpxC inhibitors.
    Müller H; Gabrielli V; Agoglitta O; Holl R
    Eur J Med Chem; 2016 Mar; 110():340-75. PubMed ID: 26866455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation, and molecular docking studies of aldotetronic acid-based LpxC inhibitors.
    Wimmer S; Hoff K; Martin B; Grewer M; Denni L; Lascorz Massanet R; Raimondi MV; Bülbül EF; Melesina J; Hotop SK; Haupenthal J; Rohde H; Heisig P; Hirsch AKH; Brönstrup M; Sippl W; Holl R
    Bioorg Chem; 2023 Feb; 131():106331. PubMed ID: 36587505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.
    Kalinin DV; Agoglitta O; Van de Vyver H; Melesina J; Wagner S; Riemann B; Schäfers M; Sippl W; Löffler B; Holl R
    Bioorg Med Chem; 2019 May; 27(10):1997-2018. PubMed ID: 30954331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibacterial activity of xylose-derived LpxC inhibitors - Synthesis, biological evaluation and molecular docking studies.
    Dreger A; Hoff K; Agoglitta O; Hotop SK; Brönstrup M; Heisig P; Kirchmair J; Holl R
    Bioorg Chem; 2021 Feb; 107():104603. PubMed ID: 33429229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of flexible and conformationally constrained LpxC inhibitors.
    Löppenberg M; Müller H; Pulina C; Oddo A; Teese M; Jose J; Holl R
    Org Biomol Chem; 2013 Sep; 11(36):6056-70. PubMed ID: 23917427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of triazolyl-substituted benzyloxyacetohydroxamic acids as LpxC inhibitors.
    Hoff K; Mielniczuk S; Agoglitta O; Iorio MT; Caldara M; Bülbül EF; Melesina J; Sippl W; Holl R
    Bioorg Med Chem; 2020 Jul; 28(13):115529. PubMed ID: 32386952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
    Szermerski M; Melesina J; Wichapong K; Löppenberg M; Jose J; Sippl W; Holl R
    Bioorg Med Chem; 2014 Feb; 22(3):1016-28. PubMed ID: 24412340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of enantiomerically pure glyceric acid derivatives as LpxC inhibitors.
    Tangherlini G; Torregrossa T; Agoglitta O; Köhler J; Melesina J; Sippl W; Holl R
    Bioorg Med Chem; 2016 Mar; 24(5):1032-44. PubMed ID: 26827141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties.
    Pirrung MC; Tumey LN; McClerren AL; Raetz CR
    J Am Chem Soc; 2003 Feb; 125(6):1575-86. PubMed ID: 12568618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents.
    Ding S; Dai RY; Wang WK; Cao Q; Lan LF; Zhou XL; Yang YS
    Bioorg Med Chem Lett; 2018 Jan; 28(2):94-102. PubMed ID: 29233653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
    McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
    Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
    Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation of Pseudomonas aeruginosa LpxC Inhibitors.
    Zuo K; Liang L; Du W; Sun X; Liu W; Gou X; Wan H; Hu J
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold.
    Liang X; Lee CJ; Chen X; Chung HS; Zeng D; Raetz CR; Li Y; Zhou P; Toone EJ
    Bioorg Med Chem; 2011 Jan; 19(2):852-60. PubMed ID: 21194954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups.
    Pirrung MC; Tumey LN; Raetz CR; Jackman JE; Snehalatha K; McClerren AL; Fierke CA; Gantt SL; Rusche KM
    J Med Chem; 2002 Sep; 45(19):4359-70. PubMed ID: 12213077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based discovery of LpxC inhibitors.
    Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
    Zhang J; Zhang L; Li X; Xu W
    Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and stereoselective synthesis of a C-aryl furanoside as a conformationally constrained CHIR-090 analogue.
    Oddo A; Holl R
    Carbohydr Res; 2012 Oct; 359():59-64. PubMed ID: 22925765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.